Catherine was appointed an independent member and chair of the audit committee of the Biotalys Board in June 2021. She brings a wealth of experience in finance, capital markets and life sciences to the Biotalys Board. Most recently, Catherine was the chair and CEO of MedDay Pharmaceuticals. She currently is a non-executive board member in various other life sciences companies, both listed (Ironwood Pharmaceuticals, Orphazyme) and privately owned (CMR Surgical).
In the recent past, she held various other senior executive roles (Innate Pharma) and board memberships in companies such as Kymab, Ablynx, Genkyotex, Zealand Pharma and Creabilis. Earlier, she was the CFO of Movetis, overseeing the company’s IPO on Euronext and subsequent sale to Shire.
Catherine started her career in investment banking and capital markets and worked in this industry for several years in the US and London, switching to corporate roles in life sciences 20 years ago. She holds an MBA and a Masters in Economics from Yale University.